Eli Lilly signed a licensing agreement with Incyte to collaborate on the development and commercialisation of oral anti-inflammatory and autoimmune therapies, the companies announced on Monday. The deal, which could be worth more than $755 million for Incyte, includes the oral JAK1/JAK2 inhibitor INCB28050, currently in mid-stage testing for rheumatoid arthritis, as well as certain follow-on compounds.
Under the terms of the deal, Eli Lilly will make a $90-million upfront payment to Incyte for exclusive global rights to develop and market INCB28050 as an oral treatment for all inflammatory conditions. Incyte will also be eligible to receive up to $665 million in milestones, plus royalties on future sales, if approved.
The companies explained that the agreement gives Incyte "the option to co-develop its JAK1/JAK2 inhibitors with Eli Lilly on a compound-by-compound and indication-by-indication basis," as well as the option to co-promote products in the US.
To read more Top Story articles, click here.